Various mutations have accumulated since the first genome sequence of SARS-CoV2 in 2020.
Mutants of the virus carrying the D614G and P681R mutations in the spike protein are increasingly
becoming dominant all over the world. The two mutations increase the viral infectivity and severity
of the disease. This report describes an in silico design of SARS-CoV-2 multi-epitope carrying the
spike D614G and P681R mutations. The designed vaccine harbors the D614G mutation that increases
viral infectivity, fitness, and the P681R mutation that enhances the cleavage of S to S1 and S2 subunits.
The designed multi-epitope vaccine showed an antigenic property with a value of 0.67 and the
immunogenicity of the predicted vaccine was calculated and yielded 3.4. The vaccine construct
is predicted to be non-allergenic, thermostable and has hydrophilic nature. The combination of
the selected CTL and HTL epitopes in the vaccine resulted in 96.85% population coverage globally.
Stable interactions of the vaccine with Toll-Like Receptor 4 were tested by docking studies. The
multi-epitope vaccine can be a good candidate against highly infecting SARS-CoV-2 variants.
